Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 8NIH 3NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Multiple Myeloma 19Lymphoma 3Neoplasms, Plasma Cell 2Smoldering Multiple Myeloma 1Sezary Syndrome 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1

Interventions

mogamulizumab 1liposomal amphotericin B 1ixabepilone 1imetelstat 1atezolizumab 1Watchful Waiting 1Vorinostat 1Vincristine 1Vancomycin 1VAP-cyclo protocol 1Tazobactam 1Radiotherapy 1Prednisone 1Piperacillin, Tazobactam Drug Combination 1Piperacillin 1Palliative Care 1Nutritional Support 1Nicotine 1Moxifloxacin 1Morphine 1Methoxsalen 1Methotrexate 1Lenalidomide 1Introns 1Interferon alpha-2 1Etoposide 1EPOCH protocol 1Doxorubicin 1Dextromethorphan 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Lymphoma, T-Cell, Cutaneous × Lenalidomide × Clear all
NCT01098656 2018-07-09

Lenalidomide Maintenance Post-debulking in Advanced CTCL

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Terminated
21 enrolled
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡